Explore Before you
decide
We'll send you 30–40 pages spanning the executive summary, methodology, and one regional deep-dive chapter.
Free to access, right away.
REPORT IN CONTEXT
Kinase Inhibitor in Autoimmune Diseases Market: One Trial, a Class Warning, and the Selectivity Escape
PublishedSep 2026
Pages350
Horizon2026-2036
LEAD ANYLYST
AB
Alice BallengerHead of Research · Healthcare